Nizar Mahomed

Arthritis Innovation Corp. operates as a clinical-stage pharmaceutical company addressing unmet needs in Orthopedic surgery and Arthritis management. Its first drug in Phase 2 clinical testing uses sustained local delivery of an NSAID after total knee replacement to manage pain and inflammation as an alternative to oral NSAIDs or narcotics. The company was founded in 2013 and is headquartered in Toronto, Canada.

Arthritis Innovation Corp. operates as a clinical-stage pharmaceutical company addressing unmet needs in Orthopedic surgery and Arthritis management. Its first drug in Phase 2 clinical testing uses sustained local delivery of an NSAID after total knee replacement to manage pain and inflammation as an alternative to oral NSAIDs or narcotics. The company was founded in 2013 and is headquartered in Toronto, Canada.

Arthritis Innovation Corp. operates as a clinical-stage pharmaceutical company addressing unmet needs in Orthopedic surgery and Arthritis management. Its first drug in Phase 2 clinical testing uses sustained local delivery of an NSAID after total knee replacement to manage pain and inflammation as an alternative to oral NSAIDs or narcotics. The company was founded in 2013 and is headquartered in Toronto, Canada.

Arthritis Innovation Corp. operates as a clinical-stage pharmaceutical company addressing unmet needs in Orthopedic surgery and Arthritis management. Its first drug in Phase 2 clinical testing uses sustained local delivery of an NSAID after total knee replacement to manage pain and inflammation as an alternative to oral NSAIDs or narcotics. The company was founded in 2013 and is headquartered in Toronto, Canada.